Search

Background: Most studies have evaluated serum C-reactive protein (CRP) levels in chronic periodontitis (CP) patients, and a few investigations have examined gingival crevicular fluid (GCF) CRP levels. The aims of this study were to determine GCF and serum levels of high-sensitivity CRP (HsCRP) in CP patients with or without coronary artery disease (CAD) and to investigate the relationship between the GCF and serum HsCRP levels in CP patients with and without CAD., Methods: Thirty CP patients with angiographically proven CAD, 20 CP patients, and 17 healthy individuals were included in the study. Clinical parameters were recorded, and serum and GCF samples were collected. The level of HsCRP in GCF was assayed by a high-sensitivity enzyme-linked immunosorbent assay. The HsCRP level was assayed in the plasma on a nephelometer., Results: The serum HsCRP levels were significantly higher in CP patients with or without CAD than in the control group, and there was a correlation between serum HsCRP levels and clinical parameters and between serum HsCRP levels and GCF volume. There was no statistically significant difference in GCF HsCRP levels between the groups. There was no correlation between GCF HsCRP levels and clinical parameters, GCF volume, or serum HsCRP levels., Conclusions: Patients with CP and CP + CAD had statistically significant elevations in serum HsCRP levels compared to healthy subjects. However, HsCRP levels of GCF did not differ from those of the control and CP groups or the control and CP + CAD groups. Further studies are needed to clarify the relationship between GCF CRP levels and periodontal diseases.

Background: Cigarette smoking has been identified as an important risk factor for the initiation and progression of chronic periodontitis (CP). The aim of this study was to investigate the effects of phase I periodontal therapy and adjunctive flurbiprofen administration on matrix metalloproteinase (MMP)-8 levels in gingival crevicular fluid (GCF) samples from smoking and non-smoking patients with CP., Methods: Twenty-nine non-smoking and 29 smoking patients with CP were divided into four groups according to periodontal treatment modalities. Group 1 (non-smokers with CP) and group 3 (smokers with CP) patients received daily 100-mg flurbiprofen tablets in a 2 x 1 regimen for 10 days together with scaling and root planing (SRP). Patients in group 2 (non-smokers with CP) and group 4 (smokers with CP) received placebo tablets in a 2 x 1 regimen for 10 days together with SRP. Plaque index (PI), gingival index (GI), probing depth (PD), and clinical attachment level (CAL) measurements were recorded; GCF samples were collected from each sampling area at baseline and after the 10-day period of drug intake by a single examiner who was unaware of the treatment modality. Assays for GCF MMP-8 were carried out by an enzyme-linked immunosorbent assay., Results: All groups showed statistically significant reductions in PI and GI scores following the phase I periodontal treatment (P < 0.05), but no statistical differences were observed in PD and CAL scores after therapy. In all groups, the reduction of GCF MMP-8 levels after therapy was statistically significant compared to baseline levels (P < 0.001). When groups 1 and 3 and 2 and 4 were compared according to GCF MMP-8 levels after the therapy, no statistically significant differences were observed (P = 0.117 and P = 0.485, respectively)., Conclusion: Flurbiprofen administration had no additional inhibitory effect over SRP alone on GCF levels of MMP-8 in smokers compared to non-smokers with CP.